PRMT1 and neoplasm: Notably, PRMT1 inhibition alone restricted neither tumor growth nor overall survival of CT26 or MC38, while the combination of PRMT1 inhibition and anti-PD-1 antibody substantially slowed tumor growth and increased the survival rate in both CT26 and MC38 tumor-engrafted mouse models (Fig. 6n–e, Supplementary Fig. 6b–e).